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Background: Elevated levels of the inflammatory cytokine TNF-α are common in chronic diseases or inherited or
degenerative muscle disorders and can lead to muscle wasting. By contrast, IGF1 has a growth promoting effect on
skeletal muscle. The molecular mechanisms mediating the effect of TNF-α and IGF1 on muscle cell differentiation
are not completely understood. Muscle cell proliferation and differentiation are regulated by microRNAs (miRNAs)
which play a dominant role in this process. This study aims at elucidating how TNF-α or IGF1 regulate microRNA
expression to affect myoblast differentiation and myotube formation.
Results: In this study, we analyzed the impact of TNF-α or IGF1 treatment on miRNA expression in myogenic cells.
Results reveal that i) TNF-α and IGF1 regulate miRNA expression during skeletal muscle cell differentiation in vitro,
ii) microRNA targets can mediate the negative effect of TNF-α on fusion capacity of skeletal myoblasts by targeting genes
associated with axon guidance, MAPK signalling, focal adhesion, and neurotrophin signalling pathway, iii) inhibition of
miR-155 in combination with overexpression of miR-503 partially abrogates the inhibitory effect of TNF-α on myotube
formation, and iv) MAPK/ERK inhibition might participate in modulating the effect of TNF-α and IGF1 on miRNA
abundance.
Conclusions: The inhibitory effects of TNF-α or the growth promoting effects of IGF1 on skeletal muscle differentiation
include the deregulation of known muscle-regulatory miRNAs as well as miRNAs which have not yet been associated with
skeletal muscle differentiation or response to TNF-α or IGF1. This study indicates that miRNAs are mediators of the
inhibitory effect of TNF-α on myoblast differentiation. We show that intervention at the miRNA level can ameliorate the
negative effect of TNF-α by promoting myoblast differentiation. Moreover, we cautiously suggest that TNF-α or IGF1
modulate the miRNA biogenesis of some miRNAs via MAPK/ERK signalling. Finally, this study identifies indicative
biomarkers of myoblast differentiation and cytokine influence and points to novel RNA targets.
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miRNA biogenesis, MAPKBackground
Detailed understanding of the molecular mechanisms
through which external stimuli such as inflammatory cyto-
kines or growth factors modulate skeletal muscle differen-
tiation is vital for the appreciation of muscle regeneration.
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unless otherwise stated.for muscle repair which involves multiple steps such as
myoblast proliferation, migration, alignment, recognition,
adhesion, cell fusion, and reorganization of the extra cellu-
lar matrix [1]. IGF1 can promote muscle differentiation
[2] and can enhance muscle maintenance and repair [3].
The underlying regulatory mechanism is not completely
understood. However, a better understanding of IGF1 sig-
nalling in skeletal muscle is important for therapeutic ap-
plication [3]. In many chronic diseases or muscular
disorders, inflammatory cytokine levels such as TNF-α are
elevated [4-6]. TNF-α is associated with cachectic muscle
wasting [7] and inhibits skeletal muscle differentiation at
higher concentrations [8].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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such as microRNAs (miRNAs) are increasingly recog-
nized as differentially regulating protein expression and
playing a key role in skeletal muscle differentiation, re-
pair and maintenance [9,10]. Moreover, miRNA expres-
sion is deregulated in many muscular disorders [11] in
which secondary processes involve persistent inflamma-
tion and impaired muscle regeneration [12]. Various
therapeutic strategies are currently being investigated to
promote skeletal muscle growth and regeneration [13].
Nuclear factor kappa B (NF-κB) links the inhibition of
muscle differentiation by inflammatory cytokines [14]
such as TNF-α to the negative regulation of myogenic
regulatory factors (MRFs) [15,16], while IGF1 increases
MRF expression [17]. As some muscle-regulatory miR-
NAs are regulated by these MRFs [18], we hypothesized
that miRNAs may be potent mediators of TNF-α and
IGF1 signalling during myoblast differentiation. Consistent
with this hypothesis, miRNAs expression is affected dur-
ing skeletal muscle wasting induced by TWEAK [19], a
member of the TNF superfamily with multiple biological
activities [20]. However, the transcriptomic response and
the regulation of miRNAs in skeletal myoblast differenti-
ation upon TNF-α or IGF1 exposure have, to the best of
our knowledge, not yet been described. Therefore, we
assessed the effects of TNF-α and IGF1 on differentiation
of skeletal myoblasts in vitro and analyzed the miRNA ex-
pression status in early skeletal muscle cell differentiation
revealing that miRNA expression is modulated by these
cytokines, possibly by MAPK/ERK signalling. Further-
more, functional miRNA studies indicated that the
impact of TNF-α and IGF1 on myotube formation in-
volved with specific miRNA activity. Finally, our study
provides valuable insights into a more detailed under-
standing of how TNF-α and IGF1 effects are mediated
via miRNA expression.
Results
Myoblast differentiation regulates miRNAs which have
not been associated with skeletal muscle physiology
Differentiation of murine cell line and human primary
skeletal myoblasts was induced in vitro by serum with-
drawal. After 24 hours we studied the impact of myogenic
differentiation on miRNA expression. We identified a sig-
nificant regulation of miRNAs which are among the 15%
most abundantly expressed species in myoblasts or
myotubes (Table 1, complete list in Additional file 1A,B).
MiRNAs which are at least four-fold upregulated or
downregulated during human or murine skeletal myoblast
differentiation are listed in Table 1. We confirmed upregu-
lation of miR-1, miR-133a, miR-133b and miR-206, which
have previously been extensively implicated in skeletal
muscle development and function [21]. A subset of seven
differentially regulated miRNAs was simultaneouslyretrieved in the human and the murine skeletal muscle
cells: miR-1, miR-133a-3p, miR-133b, miR-135a-3p,
miR-206, miR-450b-5p, miR-451a, and miR-497-5p
(Table 1A,B, Additional file 1A,B). Moreover, we identi-
fied several miRNAs which, to the best of our know-
ledge, have not been detected in skeletal myoblast
differentiation before, such as mmu-miR-202-3p, mmu-
miR-344-3p, mmu-miR-376b-5p, mmu-miR-409-3p, and
hsa-miR-216a-5p (Additional file 1A,B). In addition, our
data revealed regulation of miRNAs for which only an iso-
form or the corresponding 3p or 5p miRNA have previ-
ously been described in myoblast differentiation such as
mmu-miR-322-3p (Additional file 1A,B). In vitro myoblast
differentiation also involved miRNAs which are differen-
tially expressed in primary muscular disorders (e.g. mmu-
miR-146a-5p, mmu-miR-335-5p, hsa-miR-299-5p [11]),
aged muscle (e.g. mmu-miR-434-5p [22], mmu-miR-451a
[23]), or insulin resistant muscle in diabetes patients (e.g.
has-miR-15a-5p [24], mmu-miR-503-5p [25]) (Additional
file 1A, B). Target prediction and enrichment analysis for
differentiation-related miRNAs revealed predicted targets
enriched for functional annotations including the spliceo-
some, RNA degradation, peroxisome proliferator-activated
receptor (PPAR) signalling pathway, and neuroactive
ligand-receptor interaction (Additional file 2A, D). More-
over, predicted miRNA targets were overrepresented in
KEGG pathways such as focal adhesion, MAPK signal-
ling, axon guidance, neurotrophin signalling, and Wnt
signalling (Figure 1A, Additional file 3A; Additional
file 4A,B).
TNF-α treatment specifically regulates and counteracts
miRNA expression during skeletal myoblast differentiation
In a next set of experiments, we examined the differen-
tial miRNA expression in TNF-α treated, differentiated
primary human and murine cell line myoblasts in vitro.
TNF-α exposure differentially regulated miRNAs in hu-
man and mouse skeletal muscle cells which are among
the 15% most abundantly expressed miRNAs (Table 1,
Additional file 1A,B). We identified miRNAs which are
significantly upregulated (e.g. mmu-miR-146a-5p, hsa-
miR-15a-5p, mmu-miR-202-3p, hsa-miR-216a-5p, hsa-
miR-218-5p, mmu-miR-721) or downregulated by TNF-α
during myogenic differentiation (e.g. mmu-miR-133b-3p,
mmu-miR-137-3p, hsa-miR-149-5p, hsa-miR-198, hsa-
miR-206, mmu-miR-409-3p, hsa-miR-433, mmu-miR-434-
5p, mmu-miR-503-5p, and mmu-miR-542-3p) (Table 1,
Additional file 1A,B). A subset of miRNA was inversely
regulated more than two-fold each during myogenic differ-
entiation and TNF-α treatment: hsa-miR-1, mmu-miR-
133a-3p, hsa-miR-133b, mmu-miR-133b-3p, mmu-miR-
202-3p, hsa-miR-206, mmu-miR-206-3p, hsa-miR-216,
mmu-miR-322-3p, mmu-miR-322-5p, mmu-miR-33-3p,
mmu-miR-335-3p, mmu-miR-335-5p, mmu-miR-409-3p,
Table 1 miRNA signatures of myoblast differentiation and TNF-α or IGF1 treatment
A
TLDA Agilent
Human miRNA (hsa-miR) Differentiation ΔΔCt TNFα ΔΔCt Differentiation log2 TNFα log2
1 2.0 −0.2 1.1 −1.1
133b ●● 2.3 −3.2 1.9 −2.0
198 1.1 −2.1 n.d. n.d.
206 ●● 2.2 −2.1 2.0 −2.1
216a-5p ●● −4.4 5.5 n.d. n.d.
218-5p 0.8 2.4 0.2 2.4
299-5p 2.2 −0.8 0.3 −0.2
433 ● 2.7 −2.1 n.d. n.d.
451a - - −2.6 0.1
B
qPCR array microarray
murine miRNA (mmu-miR) Differentiation ΔΔCt TNFα ΔΔCt IGF1 ΔΔCt Differentiation log2 TNFα log2 IGF1 log2
125b-2-3p 2.0 −0.9 −0.7 n.d. n.d. n.d.
129-5p −2.4 −0.6 0.1 n.d. n.d. n.d.
133a-3p ●● 1.1 −0.3 −0.1 2.1 −0.5 0.3
133a-5p - - - 3.4 −0.8 0.5
133b-3p ●● 2.7 −0.6 0.2 2.4 −0.5 0.4
137-3p 1.3 −2.0 −0.6 n.d. n.d. n.d.
146a-5p 0.0 3.6 −1.2 n.d. n.d. n.d.
202-3p −4.1 5.6 4.4 −1.2 1.2 −0.1
206-3p ●● 2.6 −0.3 0.1 2.5 −0.3 0.5
322-3p ● 2.5 −1.3 −0.1 1.8 −1.0 0.2
330-3p −0.7 −2.2 −6.0 2.7 −1.0 0.0
335-3p ●● 2.5 −0.9 0.0 2.7 −1.0 0.0
351-5p 2.1 −0.8 0.7 2.3 −0.9 0.4
434-5p 0.8 −2.1 0.3 n.d. n.d. n.d.
451a −5.2 −4.3 1.2 n.d. n.d. n.d.
468-3p - - - −0.8 −1.4 −2.0
483-3p ● 2.6 0.4 0.2 0.6 0.4 0.3
503-3p 2.4 −0.8 0.3 n.d. n.d. n.d.
503-5p 1.4 −1.3 0.0 2.3 −1.7 0.1
542-3p 1.3 −1.5 0.2 2.6 −2.4 −0.7
Differential miRNA expression is depicted as deltadelta Cq or log2 (signal intensity) for (A) human and (B) murine miRNA expression profiling by qPCR or
microarrays for the effect of differentiation and TNF-α or IGF1 treatment. miRNAs with p-values < 0.05 and expression regulation > 4-fold in at least one test series are
depicted. Bold numbers indicate significant (p < 0.05) and > 2-fold regulation. Bold miRNAs imply cross-platform validation: The respective miRNAs were significantly
regulated in at least one of the treatment effects on both platforms (TLDA and Agilent). One black circle denotes if the miRNA is among the 25% most expressed miRNAs
in at least one of the treatment groups on the qPCR array. Two black circles depict miRNAs which are among the 15% most expressed miRNAs in at least one of the
treatment groups on the qPCR array. Some miRNAs could not be detected (n.d.) or were not present (dash) on one of the platforms.
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mmu-miR-877 (Table 1, Additional file 1A,B). The regula-
tion of miRNAs by TNF-α coincided with an impaired fu-
sion capacity demonstrated by a significantly reduced
fusion index (Additional file 5). Moreover, functional anno-
tations of predicted miRNA targets in the differentiationand the TNF-α treatment group include RNA degradation
and neuroactive ligand-receptor interaction (Additional
files 2B,E; 4A,B). Predicted targets of TNF-α-regulated
miRNAs are enriched in KEGG pathways such as axon
guidance, MAPK signalling, focal adhesion, neurotrophin,
Wnt and ErbB signalling pathways (Figure 1B, Additional
Figure 1 Predicted targets of murine miRNAs associated with myogenic differentiation, TNF-α or IGF1 response are enriched in specific
pathways. Selected KEGG pathways within the top 10 enriched KEGG pathways of predicted miRNA targets in mouse for (A) targets of miRNAs
which are differentially regulated during differentiation, (B) during differentiation with TNF-α exposure, or (C) IGF1 treatment.
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tional annotations of predicted targets of differentiation
and TNF-α-regulated miRNAs triggers the speculation
that the role of TNF-α in counteracting differentiation-
associated miRNAs might predominate over TNF-α spe-
cific induced or suppressed miRNA regulation.
IGF1 treatment both promotes and inversely regulates
myoblast differentiation-like miRNA expression patterns
IGF1 treatment of murine differentiating skeletal muscle
cells resulted in upregulation (e.g. mmu-miR-7b-5p,
mmu-miR-363-3p, mmu-miR-680) and downregulation
(e.g. mmu-miR-146a-5p, mmu-miR-148a-3p, mmu-miR-
330-3p, mmu-miR-468-3p) of miRNA subsets (Table 1,
Additional file 1A, B). IGF1 enhanced miRNA expression
seen in myogenic differentiation in the case of mmu-miR-
351-3p, mmu-miR-139-5p, mmu-miR-450b-5p (Table 1,
Additional file 1A, B). By contrast, mmu-miR-330-3p ex-
pression was substantially decreased by IGF1 exposition.Moreover, IGF1 treatment inversely regulated the expres-
sion of mmu-miR-7b-5p, mmu-miR-33-3p, and mmu-
miR-98-5p as compared to the expression pattern seen in
differentiating control myoblasts (Table 1, Additional file
1A,B). Regulation of miRNA expression by IGF1 coincided
with a positive effect on fusion capacity, as the fusion
index was increased by more than 30% (Additional file 5).
Furthermore, microRNAs differentially expressed in re-
sponse to IGF1 treatment showed predicted targets which
are enriched for functional annotations such as oxidative
phosphorylation, neurodegenerative diseases, axon guid-
ance, and muscle contraction (Additional files 2C, 4B). Be-
sides, target prediction analysis of IGF1-regulated miRNAs
revealed an enrichment of targets in KEGG pathways simi-
lar to control myoblast differentiation and TNF-α treat-
ment including axon guidance, MAPK signalling, focal
adhesion, and neurotrophin signalling (Figure 1C). More-
over, IGF1 regulated miRNAs are predicted to target insulin
signalling pathway-associated genes (Figure 1C).
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myoblast differentiation and TNF-α or IGF1 exposure
The regulation of miRNA expression by TNF-α and
IGF1 treatment of differentiating murine skeletal muscle
cells appears in separation of treatment groups by hier-
archical cluster analysis (Additional file 6A and B) or
principal component analysis (Figure 2A,B). The dis-
tance between treatment groups depended on the profil-
ing platform used as well as the clustering approach. We
applied dynamic principal component analysis to identify
the most relevant miRNAs explaining our observations
(Figure 2C,D). However, separation of treatment groups
became less clear or even disappeared between control
myotubes and TNF-α or IGF1-treated myotubes, whereas
myoblasts always separated from the differentiation effects.
Five miRNAs which are in the subset of miRNAs derived
from dynamic principal component analysis were identified
by the miRNA microarray as well as the qPCR-platform:
mmu-miR-133b-3p, mmu-miR-188-3p, mmu-miR-206-3p,
mmu-miR-335-3p, mmu-miR-351-3p (Table 2). In conclu-
sion, variable selection by dynamic principal component
analysis revealed distinct miRNAs identified on differentA
C
Figure 2 Principal component analyses of miRNA in early skeletal my
component analyses of murine miRNA expression profiling data after 24 h
component analysis reveals separation of treatment groups for (A) microar
(group selection myoblasts) identifies the most relevant subset of miRNAs
principal components for (C) microarray and (D) qPCR data. Axes depict pr
principal component 3 (PC 3).platforms which might be indicative biomarkers for myo-
blast differentiation.
MiRNAs potentially mediate the inhibitory effect of TNF-α
on myoblast differentiation
Functional miRNA analyses were performed in a human
skeletal muscle precursor cell line, LHCN [26] which
showed strong sensitivity to the repressive effect of TNF-α
upon myotube formation in vitro (Additional file 5). We
aimed at rescuing the inhibitory effect of TNF-α on myo-
blast fusion efficiency by i) overexpression of miRNAs
which were upregulated during differentiation in murine
PMI28 cells, primary human skeletal muscle cells (Table 1B,
Additional file 1A,B) or in human LHCN muscle cells [10]
or ii) by inhibition of miRNAs which are downregulated
during differentiation but upregulated due to TNF-α or iii)
by promoting differentiation-associated miRNA patterns
by a combination of overexpression and inhibition of miR-
NAs which are inversely regulated during control differen-
tiation and TNF-α treatment. However, overexpression or
inhibition of selected miRNAs did not outweigh the nega-
tive effect of TNF-α on fusion capacity (Figure 3A,B).B
D
oblast differentiation and TNF-α or IGF1 treatment. Principal
of induction differentiation and TNF-α or IGF1 treatment. Principal
ray and (B) qPCR data. Dynamic principal component analysis
which can describe the treatment effects and separate the effects by
incipal component 1 (PC 1), principal component 2 (PC 2), and
Table 2 miRNA subsets derived from dynamic principal
component analysis






































Murine miRNAs which are sufficient for identifying principal components as
shown in Figure 2B. Bold miRNAs are present in the microarray as well as the
qPCR subset.
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sion of miR-503 ameliorated the negative effect of TNF-α
on differentiation (Figures 3C, 4A). Overexpression of hsa-
miR-361, hsa-miR-486 or inhibition of hsa-miR-98 aloneor in combination with hsa-miR-133a overexpression en-
hanced fusion capacity in control myoblasts significantly
but was not powerful enough to rescue the TNF-α effect
(Figure 3A,B,C). Some miRNAs or inhibitors resulted in
partial detachment of the cell layer, leading to high stand-
ard deviations.MAPK/ERK may participate in modulating the effect of
TNF-α and IGF1 on miRNA abundance
According to a study by Paroo et al. [27] TAR RNA binding
protein (TRBP) phosphorylation by MAPK/ERK elevated
cell growth, possibly as a consequence of upregulating the
biogenesis of growth-stimulatory miRNAs and decreasing
miRNAs which suppress proliferation. Both, TNF-α and
IGF1 activate MAPK/ERK signalling [28-30], and resemble
two stimuli with inverse outcome on skeletal myoblast dif-
ferentiation. Thus, we hypothesized that MAPK/ERK acti-
vation by opposing extracellular signals affect miRNA
biogenesis in a different manner (Additional file 7). There-
fore, we assessed the impact of 24 h treatments with TNF-
α, IGF1, or pharmacological MAPK/ERK inhibition, as well
as simultaneous combinations of TNF-α and MAPK/ERK
inhibition or IGF1 and MAPK/ERK inhibition on the ex-
pression of myogenic differentiation markers in murine
skeletal muscle cells. Our study evaluated the effect on the
mRNA expression of myogenin (Myog), myocyte-specific
enhancing factor 2C (Mef2c), myogenic factor 5 (Myf5),
and myosin heavy chain 1 (Myh1) and the effect on myo-
genic differentiation-regulated miRNAs such as miR-1,
miR-133a, and miR-206 (Additional file 8A-D). Expression
analyses of mature and precursor miRNAs in murine skel-
etal myoblasts cautiously support the hypothesis that bio-
genesis of mature mmu-miR-1 and mmu-miR-133a can be
regulated by TNF-α, IGF1, and MAPK/ERK (Additional file
8A, B). The effect on miRNA processing seems to be i)
miRNA-specific, as precursor and mature forms of, for ex-
ample, mmu-miR-206 were similarly regulated (Additional
file 8C) rather indicating transcriptional regulation and ii)
precursor specific, as mmu-miR-1-1 and mmu-miR-1-2 or
mmu-miR-133a-1 and mmu-miR-133a-2 are distinctly af-
fected (Additional file 8A, B). MAPK/ERK might partici-
pate in mediating the effect of TNF-α and IGF1 on mature
miRNA abundance, as the effect of TNF-α and IGF1 on
miRNA expression was modulated in cells treated with
MAPK/ERK inhibitor (Additional file 8A-C). Firstly, mmu-
miR-1 or mmu-miR-206 downregulation by TNF-α was di-
minished when MAPK/ERK inhibitor was applied and
myogenic marker expression was unaffected. Secondly,
IGF1 treatment in combination with MAPK/ERK- inhibitor
treatment might have a synergistic positive effect on mmu-
miR-1, mmu-miR-133a, and mmu-miR-206 expression, as





































































































































Figure 3 Functional analysis of miRNAs in human myoblast
differentiation and TNF-α treatment. Relative fusion indices for
miRNA mimics or miRNA inhibitor transfections into human LHCN
myoblasts in the differentiation medium (black bars) or differentiation
medium with TNF-α supplementation (grey bars). (A) Transfection of
25 nM miRNA mimics or scrambled control miRNA (scrbl), (B) 50 nM
miRNA inhibitors or scrambled control inhibitors (anti-scrbl), and (C) a
combination of 75 nM miRNA inhibitor and 25 nM miRNA mimic or
respective controls. Samples with specific miRNAs or inhibitors are
shown relative to the respective scrambled reference which was set to
100% fusion index. Significant differences (p > 0.05) of relative fusion
indices are marked by an asterisk.
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widely used inhibitor of the MAPK/ERK pathway, in our
24 h-inhibition experiment, we relied on our observation
of the predicted indirect effect on synergistic upregula-
tion of myogenin, Mef2c, Myf5, and Myh1 mRNA ex-
pression along with IGF treatment and the decreased
downregulation of Myf5 and Myh1 in combination with
TNF-α exposure (Additional file 8D). It is well established
that the regulation of e.g. myogenin mRNA is highly dy-
namic, in particular within the first 24 h of robust myo-
genic induction by ITS (insulin, transferrin, selenium)
treatment [31]. The regulation of myogenin mRNA stabil-
ity is provided by a scheduled expression of RNA binding
proteins specifically determining its half-life within a range
of 2.5–10.5 h throughout the very early myogenic differen-
tiation period for 24 h. Half-life of myogenin mRNA ap-
peared to be maximal after about 20 h [31].
By contrast, the predicted half-life of myogenin protein
is 20 h. Rapid changes of the mRNA level within the first
24 h might not be reflected at the protein level. For
these technical reasons, we were reluctant to perform
western blotting to assess the protein expression level of
myogenin in our 24 h inhibition experiment. A series of
time points measured at hourly intervals will be required
to follow substantial short-term alterations both at the
mRNA and protein level.
Discussion
This study aimed at elucidating how cytokines involved
in muscle cell proliferation and differentiation affect
myotube formation by modulating miRNA expression
in vitro. Consistent with previously published data, we
detected miR-1, miR-133 and miR-206 regulation and cor-
roborated that primary human and murine skeletal muscle
cells represent bona fide cell culture models for myogenic
differentiation. Our miRNA profiling data reveals that
TNF-α and IGF1, two extracellular stimuli with opposed
effects on myoblast differentiation capacity, induced, antag-
onised or promoted the miRNA expression pattern of
human and murine skeletal muscle cell differentiation.
TNF-α mainly inversely regulates miRNAs expression
A B
Figure 4 Intervention at the miRNA level can rescue the effect of TNF-α on myotube formation. (A) TNF-α partly mediates its negative
effect on myotube formation through interfering at the miRNA level. TNF-α stimulates expression of miR-155 which is downregulated during
myoblast differentiation. Overexpression of miR-155 blocked myotube formation. TNF-α downregulated miR-503 expression during myoblast
differentiation. miR-503 expression was upregulated during myotube formation. Simultaneous inhibition of miR-155 and overexpression of
miR-503 rescued the inhibitory effect of TNF-α on myotube formation. Grey indicates validated targets Mef2a [36] and Cdc25a [38]. (B) Schematic
overview of the regulation of miRNA expression by TNF-α or IGF1 during skeletal myoblast differentiation. The width of the blue arrows or lines
indicate the relative quantity of miRNAs regulated by TNF-α or IGF1 in skeletal myoblast differentiation. TNF-α mainly inversely regulated miRNAs
expression associated with myoblast differentiation. IGF1 promoted and antagonised myogenesis associated miRNA expression. Few miRNAs are
specifically regulated by TNF-α or IGF1, and in turn, part of these miRNAs are counteracted by TNF-α or IGF1.
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promotes and antagonises myogenesis associated miRNA
expression (Figure 4B). Target predictions indicate that
miRNA functions might be enriched in the regulation of
axon guidance, focal adhesion, neurotrophin, and MAPK
signalling.
We also identified several miRNAs which have been
associated with primary muscular disorders, aged
muscle, sarcopenia, response to inflammatory stimuli,
dexamethasone treatment or muscular insulin resistance.
This is in line with the suggested negative effect of TNF-
α on muscle regeneration in Duchenne muscular dys-
trophy [32] or in sarcopenia [33].
In addition, our data revealed significant differential
regulation of novel miRNAs which, to the best of our
knowledge, have not yet been associated with skeletal
muscle cell differentiation or the effect of TNF-α on skel-
etal muscle cells before (Table 1, Additional file 1A,B).
Moreover, TNF-α inversely regulated the expression of
skeletal muscle differentiation-promoting miRNAs (e.g.
mmu-miRNA-133b-3p, hsa-miR-133b) which suggests
that the inhibitory effect of TNF-α on myoblast differenti-
ation might be mediated in part by interfering with myo-
genic differentiation-associated miRNA expression. We
identified TNF-α-deregulated miRNAs which have known
pro or anti-myogenic functions, such as the miRNA family
members miR-1 and miR-133a/-133b [34,35], miR-155
[9,36], miR-206 [34,37], miR-322-5p [38], miR-433 [39]
and miR-503-5p [38]. On the other hand, we also identi-
fied several novel skeletal myoblast differentiation-
associated miRNAs counteracted by TNF-α, which have
not been described in this context, such as miR-216 [40],
miR-409-3p [41], miR-877, or miR-202-3p. It has been
suggested that miR-202-3p is an inhibitor of proliferation
[42] and may function as a tumor suppressor [43] by tar-
geting Gli1 [44] which mediates Myf5 expression during
somitogenesis [45]. Early myogenic development duringembryogenesis is in good agreement with a role of miR-
202-3p in terminal myoblast differentiation. Moreover,
miR-202-3p is a potential factor for the repression of
PPAR-gamma coactivator 1 in acute inflammation [46]. It
remains to be determined whether TNF-α induced upregu-
lation of miR-202-3p in myoblast differentiation contributes
to an impaired differentiation phenotype. Furthermore, we
identified TNF-α and IGF1 as two stimuli with inverse ef-
fects on miR-450b-5p expression during muscle differenti-
ation. So far, miR-450b-5p downregulation has been linked
to the diabetic heart [47] but not to skeletal muscle cell
differentiation.
Based on dynamic principal component analyses, we pos-
tulate that a subset of myogenic differentiation-associated
miRNAs (mmu-miR-133b-3p, mmu-miR-188-3p, mmu-
miR-206-3p, mmu-miR-335-3p, and mmu-miR-351-5p), of
which most (four out of five) are deregulated by TNF-α ex-
posure, are indicators for the negative effect of TNF-αmyo-
blast differentiation. We speculate that those miRNAs
could be valuable biomarkers of the regenerative status of
the muscle in inflammatory contexts, or during the thera-
peutic response to anti-inflammatory substances such as
dexamethasone, which has been shown to regulate miR-
351 [48].
It is of particular interest to identify miRNAs which are
inversely regulated in control myotube formation or IGF1
treatment compared to TNF-α treated differentiating myo-
blasts, as these miRNAs might be potential mediators of
the negative effect of TNF-α on myoblast fusion. Support-
ing this hypothesis, we find that predicted targets of TNF-
α regulated miRNAs are retrieved in pathways important
for the control of myoblast differentiation. This indicates
that inversely regulating the expression of differentiation-
linked miRNAs might predominate the impact of TNF-α
on the miRNA level over miRNAs which are responsive to
TNF-α only. Indeed, shifting the expression of hsa-miR-
155 and hsa-miR-503, two miRNAs inversely regulated by
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rescued the inhibitory effect of TNF-α on myotube forma-
tion (Figure 4A). This finding might be interesting from a
therapeutic point of view, as miR-155 is upregulated in in-
flammatory condition such as rheumatoid arthritis [49] or
various primary muscle disorders [11]. Dexamethasone
treatment upregulated miR-503 expression in myotubes,
but induced atrophy [48]. Our phenotypic fusion index
assays suggested that further therapeutic exploitation of
simultaneous miR-155 inhibition in combination with
miR-503 mimics bears potential for treatment of immune-
mediated muscle atrophy.
A subset of miRNAs which was regulated in both, the
human primary skeletal muscle cells and the murine
skeletal muscle cell line, could indicate robust associ-
ation with myoblast differentiation across different
model systems. These miRNA families have been associ-
ated with TWEAK exposed myotubes, aged muscle or
Duchenne muscular dystrophy (DMD) (see Additional
file 1A,B). miR-450b-5p has not been associated with the
differentiation or pathogenesis of skeletal muscle cells,
however, our data suggests biological significance in
myoblast differentiation and response to TNF-α expos-
ure. Murine myoblasts showed a higher number of dif-
ferentially expressed miRNAs, probably due to species
differences, due to a higher differentiation velocity of
murine cells compared to human primary myoblasts, or to
a higher biological variance of human primary cells com-
pared to the murine cell line. Moreover, different detection
patterns might be the result of technical differences of
profiling technology and the respective underlying miR-
Base version. Several miRNAs were significantly regulated
on the qPCR platform, but not detected on the micro-
array. This discrepancy may reflect higher sensitivity with
real-time qPCR or suboptimal probe design in microarray
chips for the assessed cell culture systems.
Finally, we speculate that MAPK/ERK might partici-
pate in mediating the effect of TNF-α and IGF1 on
miRNA abundance. It has been shown that IGF1 initi-
ates the Raf/MEK/ERK axis [50] and that TNF-α leads
to MAP kinase activation, although with a very different
profile of activation as compared to IGF1 [51]. Further-
more, it has been reported that MAPK/ERK activity
modulates miRNA biogenesis in cancer cell lines by
phosphorylating TAR RNA binding protein (TRBP) and
stabilizing the Dicer-TRBP complex which enhances
mature miRNA production, whereas pharmacological
inhibition of MAPK/ERK decreases growth-promoting
miRNAs and increased growth-suppressive miRNAs
[27]. Our data cautiously indicates that maturation of
distinct muscle-enriched miRNAs might be regulated
by MAPK/ERK, TNF-α and IGF1, and that MAPK/ERK
inhibition rescues the inhibitory effect of TNF-α and
enhances the stimulating effect of IGF1 on somemiRNAs. Therefore, MAPK/ERK inhibition in skeletal
muscle differentiation, acting at the level of TNF-α and
IGF1 regulated miRNAs, might have therapeutic
significance.
In addition, our findings suggest that ERK inhibition
can counteract the decrease of myogenic differentiation
markers, as has been shown by Penna et al. [52]. How-
ever, our study describes for the first time the potential
role of MAPK/ERK in modulating the effect of TNF-α
and IGF1 at the miRNA expression or miRNA biogen-
esis level in skeletal myoblasts in vitro.
In summary, our findings confirm the hypothesis that
TNF-α exposure impairs skeletal myoblast differenti-
ation by interference at the miRNA level. Furthermore,
IGF1 treatment regulates miRNA expression during
myogenesis in vitro.
Conclusions
The study of miRNA expression in skeletal myoblast differ-
entiation is an emerging area of interest in skeletal muscle
regeneration research. We have identified differential
miRNA expression in differentiating myoblasts exposed to
TNF-α or IGF1 treatment. Furthermore, we corroborated
prominent muscle differentiation and neuromuscular
disease-associated miRNAs. Finally, we identified novel
miRNAs which have not previously been associated with
skeletal muscle differentiation or response to TNF-α or
IGF1. The present study indicates that muscle-regulatory
miRNAs are mediators of the inhibitory effect of TNF-α
on skeletal muscle differentiation in vitro, and suggests that
intervention at the miRNA level might be an innovative
therapeutic tool to rescue the inhibitory effect of pro-
inflammatory TNF-α on myoblast differentiation. Further
studies of this beneficial miRNA effect can pave the way
for novel intervention strategies in the context of sarcope-
nia and skeletal muscle disorders.
Methods
Cell culture
Primary human skeletal muscle cells (hSkMC), CTRL4107
(Muscle Tissue Culture Collection, Munich, Germany),
were propagated from a 34 year-old male’s diagnostic
musculus gastrocnemius biopsy (caput laterale) due to
non-specific muscular symptoms after informed consent.
The muscle biopsy showed no obvious myopathology.
HSkMCs were propagated in Skeletal Muscle Cell Growth
Medium Low Serum (PromoCell GmbH, Heidelberg,
Germany) containing 5% Supplement Mix (PromoCell),
10% foetal calf serum (FCS) (PAA Laboratories GmbH,
Pasching, Austria), and 2 mM L-glutamine (PAA Labora-
tories). HSkMCs cells were plated on laminin-1 coated
dishes. After 24 hours, the growth medium was replaced
by a differentiation medium (DMEM medium supple-
mented with 2% horse serum, Life Technologies,
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boratories). Immortalized human skeletal myoblasts
LHCN-M2 (LHCN) [26] were propagated in growth
medium containing 4 parts DMEM (Life Technologies), 1
part Medium 199, GlutaMAX Supplement (Life Technolo-
gies), 20% FCS (Sigma-Aldrich, St. Louis, MO, USA), peni-
cillin (100 I.U./ml)/streptomycin (100 μg/ml) (Life
Technologies), and 2.5 μg/ml plasmocin (InvivoGen, San
Diego, CA, USA). Prior to the induction of differentiation,
cells were seeded on collagen (Sigma-Aldrich) coated
plates for 24 hours at 2 ×104 cells/well of a 96-well plate.
Differentiation was induced by switching to a differenti-
ation medium composed of DMEM, penicillin (100 I.U./
ml)/streptomycin (100 μg/ml), insulin 0.01 mg/ml, and
transferrin 0.1 mg/ml (Life Technologies). Cytokine
treated-cells received 2 × 103 U/ml human recombinant
TNF-α (Roche Diagnostics, Rotkreuz, Switzerland) or car-
rier for the control. The same amount of TNF-α was added
every 24 hours without changing the differentiation
medium. LHCN cells were harvested 7 days after the in-
duction of differentiation for immunocytochemistry. For
in vitro studies on mouse skeletal muscle cells, the murine
skeletal myoblast cell line PMI28 [53] was cultured in
Ham’s F10 (PAA Laboratories), supplemented with 20%
FCS (Sigma-Aldrich), 2 mM L-glutamine (PAA Laborator-
ies), and Penicillin (100 I.U./ml)/Streptomycin (100 μg/ml,
PAA Laboratories). PMI28 cells were plated on laminin-1
(Sigma-Aldrich) coated dishes at 1.5 × 106 cells per 10 cm
cell culture plate. After 24 hours the growth medium was
replaced by a differentiation medium containing DMEM
medium with 2% horse serum (Gibco), 2 mM L-glutamine
(PAA Laboratories), and Penicillin (100 I.U./ml) / Strepto-
mycin (100 μg/ml) with 2 × 103 U/ml murine recombinant
TNF-α (Roche Diagnostics), 5 ng/ml murine recombinant
IGF1 (Sigma-Aldrich). For experiments analyzing the influ-
ence of MAPK/ERK activity on modulating the effect of
TNF-α and IGF1 on miRNA abundance we exposed cells
to 20 μM MEK Inhibitor U0126 (Promega Corporation,
Madison, WI, USA), or carrier, and combinations of U0126
or carrier and TNF-α or IGF1, respectively. All control and
treatment media were replenished twice a day to ensure
cytokine and growth factor activity. Murine PMI28 cells
were harvested 24 h after the induction of fusion by serum
withdrawal for RNA analyses, or after 72 hours for cyto-
chemistry. All cells were propagated at 37°C in 80% relative
humidity and 5% CO2.
Cell transfection
Human LHCN cells were transfected with different
miRNA inhibitors (miRCURY LNA microRNA Inhibitors)
or a scrambled control (miRCURY LNA microRNA In-
hibitor Control) from Exiqon (Vedbaek, Denmark) or/and
pre-miRNA precursors and precursor scrambled control
(mimics) from Ambion (Life Technologies) as follows:The transfection mix for a 96-well plate format contained
10 μl Opti-MEM I Reduced Serum Medium, GlutaMAX
Supplement (Life Technologies) per well with final
miRNA inhibitor concentrations of 25 nM, 50 nM, or 100
nM, or final miRNA mimic concentrations of 5 nM, 25
nM, or 50 nM as well as Lipofectamine RNAiMAX trans-
fection reagent (Life Technologies). The transfection mix
was incubated for 20 minutes at room temperature and
added to the well before plating 90 μl of cell suspension.
24 hours after transfection, the growth medium was
replenished or the differentiation medium with TNF-α or
IGF1 was added, respectively.
Immuno-fluorescent staining
Differentiation markers of skeletal muscle cells, such as β-
dystroglycan or myosin heavy chain were used for immuno-
fluorescence staining and detection of fusion efficiency.
Staining against β-dystroglycan was performed as follows:
Cells were fixed with 3.7% paraformaldehyde in CSK buffer
(100 mM sodium chloride, 300 mM sucrose, 10 mM PIPES
[piperazin-1,4-bis (2-ethanesulfonic acid)] pH 6.8, 3 mM
magnesium chloride, 1 mM EDTA [ethylene glycol-bis (β-
aminoethyl ether)-N,N,N’,N’-tetraacetic acid)], washed with
0.15% glycine in phosphate buffered saline (PBS) three
times, and blocked with 5% horse serum in PBS. The beta-
dystroglycan mouse monoclonal antibody (NCL-ß-DG,
Novocastra Laboratories Ltd, Newcastle upon Tyne, United
Kingdom) was incubated in a dilution of 1:20. After wash-
ing with 0.15% glycine in PBS Cy3-labeled the secondary
antibody, anti-mouse IgG (whole molecule) Cy3 conjugate,
F (ab’)2 fragment of sheep antibody (Sigma-Aldrich), diluted
1:200 was incubated. Cells were washed with 0.15% glycine
in PBS with a 20 μg/ml DAPI [4′,6-Diamidino-2-phenylin-
dole dihydrochloride] (Fluka Chemie AG, Neu-Ulm,
Germany) and 0.15% glycine in PBS. Afterwards, cells were
embedded in a DAKO Fluorescent Mounting Medium
(DAKO, Carpinteria, CA, USA). For the automated analysis
of 96-well plate format transfection experiments, cells were
fixed with 4% paraformaldehyde in PBS, washed with
100 mM glycine in PBS, then washed with PBS and perme-
abilized with 0.2% Triton X-100 in PBS. After washing with
PBS, cells were blocked with IMAGE-iT FX signal enhan-
cer (Life Technologies). For the immunostaining of myosin
heavy chain, anti-MHC antibody (Sigma MY-32) was used
at a dilution of 1:600. Cells were rinsed with PBS and incu-
bated with the Alexa Fluor 488-labeled secondary anti-
mouse antibody (Invitrogen, Life Technologies) diluted to
1:500. After washing with PBS, cells were incubated with
8 μM Hoechst 33258. Washing with PBS preceded the cov-
ering of cells with PBS containing 1% paraformaldehyde.
Microscopy and image analysis
Images of murine skeletal muscle cells PMI28 stained
against beta-dystroglycan were recorded by conventional
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seconds for DAPI and 1000 milliseconds for Cy3 staining at
100-fold or 200-fold magnification. Merged-images were
analyzed by counting nuclei with the CellProfiler Software
[54]. As a measure of terminal differentiation efficiency, the
fusion index was calculated as the mean percentage of nu-
clei in myotubes divided by the total number of nuclei.
Myotubes were defined as β-dystroglycan positive struc-
tures containing at least three nuclei. Human skeletal
muscle cells LHCN used in the transfection experiments
were analyzed on an Operetta High Content Screening sys-
tem (Perkin Elmer, Waltham, MA, USA). Nuclei and myo-
tubes were identified by applying intensity thresholds, area
and shape parameters according to Polesskaya et al. [10].
RNA extraction and quality control
For miRNA profiling, about 2 × 106 cells were harvested
in 1.5 ml Trizol (Life Technologies), homogenized,
mixed with 0.45 ml chloroform and phase separated by
centrifugation. RNA was precipitated by aspiration of
the upper aqueous phase, addition of 1.25 ml isopropa-
nol, mixing and centrifugation. The pellet was washed
with 75% ethanol, then dried and dissolved in water.
Total RNA concentrations were determined photomet-
rically using the NanoDrop 1000 ND-1000 (Peqlab, Er-
langen, Germany). Overall RNA quality was assessed on
a 1% agarose gel with a 1 KB molecular weight marker
separated in parallel. Cells from MEK-inhibitor experi-
ments were lyzed with 700 μl Qiazol (Qiagen, Hilden,
Germany), thoroughly mixed with 140 μl chloroform
and centrifuged at 12,000 × g at 4°C for 15 minutes. The
upper aqueous phase was mixed with 1.5 volumes of
ethanol and loaded onto an RNeasy Mini spin column
(RNeasy Mini Kit, Qiagen). RNA extraction was per-
formed according to the manufacturer’s instructions.
Reverse transcription of RNA to cDNA for individual
expression analysis
For the analysis of miRNA by individual assays, total RNA
was reverse transcribed using the miScript RT Kit (Qiagen)
according to the manufacturer’s instructions. For the ana-
lysis of mature miRNAs, precursor miRNA and mRNA
from the same reverse transcription reaction total RNA
was first treated with DNase using the TURBO DNA-free
kit (Life Technologies) according to the manufacturer’s in-
structions prior to reverse transcription.
MicroRNA profiling by microarray technology
microRNA expression of primary human or murine cell
line skeletal muscle cells were performed by using Agilent
Human MicroRNA Microarray V2 (8×15K, G4471A-
019118 Agilent Technologies, Santa Clara, CA, USA)
which contained probes for 723 human microRNAs from
the Sanger miRBase v10.1 (www.mirbase.org) and by usingMouse miRNA Microarray Release 15.0 (8×15K, G4471A-
029152, Agilent Technologies) which contained probes for
696 miRNAs from Sanger miRBase release 15.0. Quadru-
plicate or triplicate samples of myoblasts, differentiated
myotubes, and TNF-α or IGF1 treated myotubes were
included in the study. 100 ng total RNA was used for Cy3-
labeling of miRNAs by using the miRNA Complete Label-
ing and Hybridization Kit (Agilent Technologies) according
to the manufacturer’s instructions. Samples were loaded
onto the array and hybridized at 55°C for 20 hours. Micro-
RNA microarrays were washed and scanned with the Agi-
lent Microarray Scanner G2505C in a single pass mode
with a scan resolution of 3 μm, 20 bit mode. Signal inten-
sities were extracted and background subtracted using Fea-
ture Extraction Software 10.7.3.1 (Agilent Technologies).
MicroRNAs which passed the filtering criterion “well above
background” in at least two of the replicates within one
group were retained. 282 miRNAs met these detection cri-
teria. Data was normalized by loessM normalization
[55,56]. Agilent microarray data was MIAME [57] compli-
ant and was registered into the ArrayExpress database
(www.ebi.ac.uk/arrayexpress) [58], a publicly available re-
pository consistent with the MIAME guidelines. Data is
available with the ArrayExpress accession number E-
MTAB-1114 (murine data) or E-MTAB-299 (human data).
MicroRNA profiling by quantitative qPCR
MicroRNA expression profiling by qPCR was based on
TaqMan Array Human MicroRNA Panel v 1.0 (Life
Technologies) and TaqMan Rodent MicroRNA Arrays
2.0 (Life Technologies) using TaqMan chemistry accord-
ing to the manufacturer’s instructions. Three separate
reverse transcription reactions per sample were per-
formed. For the murine samples each reverse transcrip-
tion reaction was preamplified using the Megaplex
PreAmp Primers Rodent Pool A and Rodent Pool B (Life
Technologies) according to the manufacturer’s instruc-
tions. The three separate reverse transcription and pre-
amplification reactions per sample were pooled per
original sample and the qPCR reaction mix was prepared
according to the manufacturer’s instructions. The array
was run on an Applied Biosystems 7900HT Fast Real-
Time System with cycling conditions according to the man-
ufacturer’s protocol. Raw expression data was obtained
using SDS 2.3 software (Applied Biosystems, Life Technolo-
gies). SDS files were loaded into the RQ Manager 1.2
software (Applied Biosystems, Life Technologies). The
threshold was manually set to 0.2. Each amplification plot
was reviewed manually and the threshold settings were ad-
justed for individual assays if necessary. MicroRNAs which
showed Cq-values smaller than 32 in at least two of the
corresponding triplicates of a group were retained for fur-
ther data processing. Data was normalized by loessM
normalization [55,56] using R programming [59].
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Individual qPCR reactions were performed for mature
and precursor miRNAs using miScript SYBR Green PCR
Kit (Qiagen) and the respective miScript Primer Assay
(Qiagen) or miScript Precursor Assay (Qiagen) accord-
ing to the manufacturer’s protocol and were run on a
RotorGene Q Real-time PCR cycler (Qiagen).
Statistics
Significant differences between fusion indices or individ-
ual qPCR analyses were determined by using parametric
unpaired two-tailed Student’s t-test. Relative quantifica-
tion [60] of miRNA expression levels derived from pro-
filing experiments was tested for significant differences
by applying significance analysis of microarrays (SAM)
[61] which uses permutation. In addition, false discovery
rate (FDR) correction of p-values was performed. Signifi-
cance analysis and FDR correction were performed by R
programming [59].
Bioinformatics analysis of data
Dynamic principal component analysis (PCA) was per-
formed within GenEx Software (MultiD Analyses AB,
Gothenburg, Sweden) comparing myoblasts to the other
treatment groups. MiRNAs were filtered by p-values to
identify the most relevant genes or miRNAs explaining
the observations. The miRSystem [62] bioinformatics tool
was applied to identify enriched functions and pathways of
miRNA targets using KEGG database information [63].
Additional files
Additional file 1: (Microsoft excel document): miRNA signatures of
myoblast differentiation and TNF-α or IGF1 treatment. Differential
miRNA expression is depicted as deltadelta Cq or log2 (signal intensity)
for (A) murine and (B) human miRNA expression profiling by qPCR or
microarrays, respectively. Results with p-values <0.05 and regulation >2-fold
are depicted in bold. Bold miRNAs indicate cross-platform validation which
means that at least one of the treatment effects was validated (significant
and >2-fold regulation) on both platforms. One black circle indicates
miRNAs detected among the 25% most expressed, two black circles mark
miRNAs among the 15% most expressed miRNAs in at least one of the
treatment groups on the qPCR array. Some miRNAs are not present on one
of the platforms which is indicated by a dash. Some miRNAs could not be
detected (n.d.) although present on the platform. Comments or references
in parentheses indicate that the information applies to an isoform of the
respective miRNA or the corresponding 3p- or 5p-strand instead of the miRNA
indicated in the table. Lacking references indicate that, to the best of our
knowledge, there was no previous report of differential miRNA expression
during skeletal muscle differentiation, TNF-α or IGF1 treatment of skeletal
myoblasts or myotubes or in pathological skeletal muscle conditions.
Additional file 2: (Microsoft word document): Predicted targets of
human and murine miRNAs associated with myogenic differentiation,
TNF-α or IGF1 response are enriched in selected specific functional
annotations. Murine miRNA targets are enriched in functional annotations
during (A) myoblast differentiation, (B) TNF-α treated, and (C) IGF1 treated
differentiating myoblasts. Predicted human miRNA targets are enriched in
functional annotations during (D) myoblast differentiation and (E) myoblast
differentiation with TNF-α treatment. The complete list can be found in
Additional file 4A, B).Additional file 3: (Microsoft word document): Human miRNAs
associated with myogenic differentiation and TNF-α response are
predicted to target genes which are enriched in specific pathways.
Selected KEGG pathways within the top 10 enriched pathways of
predicted miRNA targets of differentially regulated human miRNAs.
(A) KEGG pathways of human myoblast differentiation, (B) KEGG
pathways of human myoblast differentiation with TNF-α exposure.
The complete list can be found in Additional file 4A.
Additional file 4: (Microsoft excel document): Functional
annotation and enrichment of predicted miRNA targets in KEGG,
Reactome, Biocarta, Pathway Interaction Database, or gene
ontology term molecular function. Predicted targets of (A) human and
(B) murine miRNAs associated with myogenic differentiation, TNF-α or
IGF1 response and their enrichment in specific pathways and functional
annotations based on different databases and terms.
Additional file 5: (Microsoft word document): Differentiation
efficiency of skeletal muscle cells is negatively regulated by TNF-α
while slightly enhanced by IGF1 treatment. The fusion efficiency of
differentiating murine PMI28 skeletal myoblasts (black bars) on day three
of differentiation treated with TNF-α (TNF) or IGF1 (IGF) are represented.
Relative fusion indices give the ratio of nuclei in myotubes and total amount
of nuclei relative to the control. Fusion indices of human LHCN myoblasts
were analysed on day 7 after the induction of differentiation (grey bars). The
effect of IGF1 on human LHCN myoblast fusion was not tested.
Additional file 6: (PNG file): Hierarchical clustering and heatmaps of
miRNA expression profiling after 24 h of induction of differentiation
and TNF-α or IGF1 treatment. Hierarchical clustering analysis of (A) miRNA
microarray profiling data after 24 h of induction of differentiation reveals
clear clustering of myoblasts (MB) and most of the myoblast samples
treated with TNF-α (TNF). Myoblasts and myotubes (MT) with TNF-α
treatment have a large distance to control myotubes and myotubes with
IGF1 (IGF), indicating that TNF-α impairs differentiation. (B) Hierarchical
clustering analysis of miRNA qPCR data reveals separation of the IGF1
treated myotubes from the other samples.
Additional file 7: (JPEG file): TNF-α and IGF1 may modulate skeletal
muscle-related miRNA abundance and biogenesis via MAPK/ERK
signalling. We hypothesized that activation of MAPK/ERK by TNF-α or
IGF1 exposure modulates miRNA abundance and biogenesis of skeletal
muscle-related miRNAs and myogenic differentiation marker. We postulated
that the effects of TNF-α or IGF1 treatment on miRNA expression are dis-
tinctly modulated by MAPK/ERK activity.
Additional file 8: (Microsoft word document): Effect of TNF-α, IGF1,
and MAPK/ERK-Inhibitor on mature and precursor miRNA
abundance and differentiation marker expression. qPCR based
relative gene expression analysis results of mature and precursor miRNA
and selected mRNAs of early murine myoblast differentiation (24 h)
treated with TNF-α (TNF), IGF1 (IGF), or MAPK/ERK-inhibitor (MAPK-I) or
simultaneous combinations thereof are shown. Mature miRNAs are
depicted in black and the sum of primary and precursor (PR) miRNAs is
shown in red or green. (A) miR-1 (black bar), miR-1-1 precursors (red bar),
miR-1-2 precursors (green bar), (B) miR-133a (black bar), miR-133a-1
precursors (red bar), miR-133a-2 precursors (green bar), (C) miR-206
(black bar), miR-206 precursors (red bar), (D) Relative mRNA expression of
myogenin (Myog), myocyte enhancer factor 2C (Mef2c), myogenic factor 5
(Myf5), and myosin heavy chain 1 (Myh1). Asterisks indicate significant
differential expression with a p-value < 0.05 and more than 1.5-fold change.
MAPK-I: MAPK/ERK-inhibitor treatment; MAPK-I (TNF): MAPK/ERK-inhibitor
treatment of cells exposed to TNF-α; TNF: TNF-α treatment; TNF (MAPK-I):
TNF-α treatment of cells with MAPK/ERK inhibition; MAPK-I (IGF): MAPK/
ERK-inhibitor treatment of cells exposed to IGF1; IGF: IGF1 treatment;
IGF (MAPK-I): IGF1 treatment of cells with MAPK/ERK inhibition. Gray
boxes contain a minus if cells were not exposed to MAPK-I or a cytokine
(TNF or IGF). A plus indicates treatment with the respective substance.
A bold plus indicates the treatment difference relating to the respective
control and thus depicts the measured treatment effect.
Abbreviation
CTRL4107: Primary human skeletal muscle cells 4107; Dicer: Dicer 1,
ribonuclease type III; DMD: Duchenne muscular dystrophy; DMEM: Dulbecco’s
Meyer et al. Cell Communication and Signaling  (2015) 13:4 Page 13 of 14modified eagle medium; ErbB: v-erb-b2 erythroblastic leukemia viral oncogene
homolog; FCS: Foetal calf serum; Gli1: GLI family zinc finger 1 (homo sapiens),
GLI-Kruppel family member GLI1 (mus musculus); hSkMC: Primary human
skeletal muscle cells; IGF, IGF1: Insulin like growth factor 1; LHCN: A human
skeletal muscle precursor cell line/Immortalized human skeletal myoblasts;
MAPK/ERK: Mitogen-activated protein kinase 1/extracellular signal-regulated
kinase 2; Mef2c: Myocyte-specific enhancing factor 2C; miRNA: Micro
ribonuleotide acid; MRF: Myogenic regulatory factorLHCN-M2; Myf5: Myogenic
factor 5; Myh1: Myosin heavy chain 1; Myog: Myogenin; NF-κB: Nuclear factor
of kappa light polypeptide gene enhancer in B-cells 1; PMI28: A murine
skeletal myoblast cell line [53]; PPAR: Peroxisome proliferator-activated
receptor; Raf/MEK/ERK axis: v-raf-1 murine leukemia viral oncogene homolog
1 (homo sapiens), zinc fingers and homeoboxes 2 (mus musculus)/mitogen-
activated protein kinase kinase 1/mitogen-activated protein kinase 1; TNF;
TNF-α: Tumor necrosis factor alpha; TRBP: TAR RNA binding protein;
TWEAK: Tumor necrosis factor (ligand) superfamily, member 12; U0126: MEK
Inhibitor U0126; Wnt: Wnt oncogene analog.
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